On Nov 01, major Wall Street analysts update their ratings for $Bio-Rad Laboratories (BIO.US)$, with price targets ranging from $360 to $469.
Citi analyst Patrick B Donnelly maintains with a buy rating, and adjusts the target price from $400 to $450.
UBS analyst Dan Leonard maintains with a buy rating, and adjusts the target price from $400 to $390.
Wells Fargo analyst Brandon Couillard maintains with a hold rating, and adjusts the target price from $340 to $360.
RBC Capital analyst Conor McNamara maintains with a buy rating, and adjusts the target price from $446 to $469.
Furthermore, according to the comprehensive report, the opinions of $Bio-Rad Laboratories (BIO.US)$'s main analysts recently are as follows:
Bio-Rad delivered strong third-quarter results, which are likely to be received positively by investors following a period of challenging execution.
Bio-Rad surpassed EBITDA expectations by over $30M, with $4M-$5M attributed to heightened royalties, and the remainder of the outperformance due to a combination of product mix, operational efficiencies, controlled expenditure, and revenue growth that exceeded forecasts in both business segments.
Here are the latest investment ratings and price targets for $Bio-Rad Laboratories (BIO.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
